amsacrine has been researched along with razoxane in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andoh, T; Hamatake, M; Ishida, R; Nitiss, JL; Wang, JC; Wasserman, RA | 1 |
| Holm, B; Jensen, PB; Sehested, M | 2 |
| Falck, J; Jensen, LH; Jensen, PB; Nitiss, JL; Roerth, M; Rose, A; Sehested, M; Wessel, I | 1 |
| Jensen, LH; Jensen, PB; Møller, M; Nitiss, JL; Sehested, M; Wessel, I | 1 |
| Dejligbjerg, M; Grauslund, M; Hansen, LT; Jensen, LH; Jensen, PB; Sehested, M | 1 |
6 other study(ies) available for amsacrine and razoxane
| Article | Year |
|---|---|
DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.
Topics: Amsacrine; Antineoplastic Agents; Diketopiperazines; DNA Topoisomerases, Type II; Drug Hypersensitivity; Drug Resistance; Piperazines; Razoxane; Saccharomyces cerevisiae; Topoisomerase II Inhibitors | 1995 |
ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Ehrlich Tumor; Central Nervous System Neoplasms; DNA Topoisomerases, Type II; Etoposide; Female; Injections, Intraperitoneal; Lethal Dose 50; Leukemia L1210; Male; Mice; Mice, Inbred DBA; Paclitaxel; Razoxane; Structure-Activity Relationship | 1996 |
Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Drug Administration Schedule; Etoposide; Female; Mice; Mice, Inbred Strains; Razoxane; Survival Rate; Teniposide; Topoisomerase II Inhibitors | 1998 |
Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Topics: Adenosine Triphosphate; Amino Acid Sequence; Amino Acid Substitution; Amsacrine; Animals; Antineoplastic Agents; Binding Sites; Carcinoma, Small Cell; Catalysis; CHO Cells; Consensus Sequence; Cricetinae; Cricetulus; DNA Damage; DNA Mutational Analysis; DNA Topoisomerases, Type II; DNA, Neoplasm; DNA, Single-Stranded; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Lung Neoplasms; Molecular Sequence Data; Mutagenesis, Site-Directed; Point Mutation; Protein Isoforms; Razoxane; Recombinant Fusion Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Thiobarbiturates; Topoisomerase II Inhibitors; Tumor Stem Cell Assay | 1999 |
N-terminal and core-domain random mutations in human topoisomerase II alpha conferring bisdioxopiperazine resistance.
Topics: Adenosine Triphosphate; Amsacrine; Antigens, Neoplasm; Diketopiperazines; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance; Enzyme Inhibitors; Etoposide; Humans; Isoenzymes; Mutagenesis; Nucleic Acid Synthesis Inhibitors; Piperazines; Razoxane; Topoisomerase II Inhibitors | 2000 |
Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
Topics: Amsacrine; Animals; Antineoplastic Agents; CHO Cells; Cricetinae; DNA Damage; DNA Topoisomerases, Type II; Gene Expression Profiling; Gene Expression Regulation; Humans; Mammals; Razoxane; Saccharomyces cerevisiae; Tumor Cells, Cultured | 2004 |